ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Jaume Pons

ALX Oncology Holdings Inc.

Immunome is a clinical-stage targeted oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company has an innovative portfolio of therapeutics, including antibody-drug conjugates and treatments for desmoid tumors.

Immunome

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Umoja Biopharma develops integrated platform therapeutics that reprogram the immune system to target cancer cells and generate lasting remissions.

Metric
Company Name	ALX Oncology Holdings Inc.	Immunome	Therini Bio	Umoja Biopharma
Symbol	ALXO
MSH ID	COM:ALXONCOLOGY	COM:IMMUNOME	COM:THERINIBIO	COM:UMOJA-BIOPHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Biotechnology	Biotechnology
Country	US	US	US	US
Stage
Employee Count	74
Website	alxoncology.com	immunome.com	therinibio.com	umoja-biopharma.com
LinkedIn		immunome-inc-	therinibio
Founders

Metric
Market Cap	352.20M
Enterprise Value
Monthly Web Traffic		6.83K
Web Traffic Growth		-0.19
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ALXONCOLOGY

ALX Oncology Holdings Inc.

Last Close

1.29

22/11 21:00

Market Cap

352.20M

Beta: -

Volume Today

966.09K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue